Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Dose Modification In MDS Pts Receiving Lenalidomide As a Means To Improve Patient Persistence

B. Douglas Smith, MD, Dalia Mahmoud, MBA, Stephanie Lee, Laura Weber

Blood (2013) 122 (21): 2987.

https://doi.org/10.1182/blood.V122.21.2987.2987

Published: 2013

Journal Articles

Differences In Treatment and Diagnostic Patterns In Private Vs Public Sectors For Deletion 5Q Myelodysplastic Syndromes (MDS) In Mexico: Results From A Physician Survey

Michelle Ann Soriano, PhD, Roberto Ovilla, MD, Maria Guadalupe Rodríguez-González, MD, Renée Arnold, PharmD, RPh, Dalia Mahmoud, MBA

Blood (2013) 122 (21): 5593.

https://doi.org/10.1182/blood.V122.21.5593.5593

Published: 2013

Journal Articles

Quality of Life and Productivity Impact of Myelodysplastic Syndromes (MDS): The Patient Perspective

Dalia Mahmoud, MBA, Stacie Hudgens, MS, Fiona Taylor, MBiochem, Farrah Pompilus, MA, Steve Hwang, BA, C.L. Beach, PharmD

Blood (2012) 120 (21): 4705.

https://doi.org/10.1182/blood.V120.21.4705.4705

Published: 2012

Journal Articles

Lenalidomide Performance in the Real World: Patterns of Utilization and Effectiveness in a Medicare Population with Myelodysplastic Syndromes

Amer M. Zeidan, MD, Steven D. Gore, MD, Diane L. McNally, BSPharm, M.S., Maria R. Baer, M.D., Franklin Hendrick, B.S., Dalia Mahmoud, MBA, Amy J. Davidoff, M.S., Ph.D.

Blood (2012) 120 (21): 3837.

https://doi.org/10.1182/blood.V120.21.3837.3837

Published: 2012

Journal Articles

Overall Economic Burden of Total Treatment Costs in Acute Myeloid Leukemia throughout the Course of the Disease

Dalia Mahmoud, MBA, Barry S. Skikne, MD, Izabela Kucmin-Bemelmans, MSc, Cathelijne Alleman, MSc, Marja Hensen, MSc

Blood (2012) 120 (21): 3614.

https://doi.org/10.1182/blood.V120.21.3614.3614

Published: 2012

Journal Articles

Treatment Persistence with Azacitdine (Vidaza) Is Associated with Lower Inpatient Hospitalization Costs Over Time

B. Douglas Smith, M.D., Dalia Mahmoud, MBA, Stacey Dacosta Byfield, Henry J Henk, PhD

Blood (2012) 120 (21): 4231.

https://doi.org/10.1182/blood.V120.21.4231.4231

Published: 2012

NARROW

Dose Modification In MDS Pts Receiving Lenalidomide As a Means To Improve Patient Persistence

Differences In Treatment and Diagnostic Patterns In Private Vs Public Sectors For Deletion 5Q Myelodysplastic Syndromes (MDS) In Mexico: Results From A Physician Survey

Quality of Life and Productivity Impact of Myelodysplastic Syndromes (MDS): The Patient Perspective

Lenalidomide Performance in the Real World: Patterns of Utilization and Effectiveness in a Medicare Population with Myelodysplastic Syndromes

Overall Economic Burden of Total Treatment Costs in Acute Myeloid Leukemia throughout the Course of the Disease

Treatment Persistence with Azacitdine (Vidaza) Is Associated with Lower Inpatient Hospitalization Costs Over Time

Email alerts

ASH Publications

American Society of Hematology

Dose Modification In MDS Pts Receiving Lenalidomide As a Means To Improve Patient Persistence

Differences In Treatment and Diagnostic Patterns In Private Vs Public Sectors For Deletion 5Q Myelodysplastic Syndromes (MDS) In Mexico: Results From A Physician Survey

Quality of Life and Productivity Impact of Myelodysplastic Syndromes (MDS): The Patient Perspective

Lenalidomide Performance in the Real World: Patterns of Utilization and Effectiveness in a Medicare Population with Myelodysplastic Syndromes

Overall Economic Burden of Total Treatment Costs in Acute Myeloid Leukemia throughout the Course of the Disease

Treatment Persistence with Azacitdine (Vidaza) Is Associated with Lower Inpatient Hospitalization Costs Over Time

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only